权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pandemic Assistance Core

流行病援助核心

基本信息

批准号：
10514267
负责人：
Catherine A Blish
金额：
$ 559.9万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-05-16 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10514267
关键词：
2019-nCoV A549 ACE2 Adult Air Antiviral Agents Biological Models COVID-19 therapeutics Cell Line Cells Chikungunya virus Complex Data Development Distal Dose Drug Screening Evaluation Family Picornaviridae Flaviviridae Flavivirus GS-441524 Goals Histopathology Human In Vitro Individual Industry Infection Inflammation Infrastructure Inhalation Life Cycle Stages Liquid substance Lung Middle East Respiratory Syndrome Coronavirus Modeling Morbidity - disease rate Nasal Epithelium No-Observed-Adverse-Effect Level Oral Organoids Outpatients Pathway interactions Pharmaceutical Preparations Physiological RNA Viruses Research Personnel Resources Rodent Model SARS coronavirus SARS-CoV-2 variant Series Structure System TMPRSS2 gene Testing Therapeutic Therapeutic Index Tissues Togaviridae Toxic effect Translations Universities Viral Virus Virus Diseases Virus Replication West Nile virus Work antiviral drug development drug candidate drug development drug efficacy efficacy validation experience in vivo in vivo Model in vivo evaluation indexing innovation lead candidate mortality novel therapeutics pandemic disease pathogen programs prophylactic pulmonary function remdesivir screening subcutaneous synergism targeted treatment therapeutic candidate tool virology

项目摘要

PROJECT SUMMARY/ABSTRACT The Pandemic Assistance Core will enable investigators in this AViDD center to rapidly develop antiviral therapeutics for SARS-CoV-2 and other RNA viruses of pandemic potential. This core will provide capacity for rigorous in vitro and in vivo testing of compounds developed across all seven Projects, with a particular emphasis on providing unparalleled BSL3 and ABSL3 capacity. We will quickly and efficiently refine our targets and down-select from a series of go/no-go decisions over the course of our project, providing a funnelling structure to rapidly identify the most promising candidates both in vitro and in vivo. Compounds will be tested in both prophylactic and therapeutic models. As our Projects take unique approaches to target the viral life cycle, lead candidates from each project will also be tested in combination to identify synergism. The most promising of the lead candidates will then be sent for further development within the Translation Accelerator Core. To achieve this work we have brought together an outstanding and interdisciplinary team of investigators with significant experience in virology, drug development, and rodent models for drug screening. We also bring highly innovative approaches to test compounds in physiologic systems using human air-liquid interface (ALI) models and human adult lung organoids (ALO). We aim to provide industry-level capacity for screening and selecting the most promising drug candidates.

项目总结/摘要大流行援助核心将使该AViDD中心的研究人员能够快速开发抗病毒药物， SARS-CoV-2和其他可能大流行的RNA病毒的治疗剂。这一核心将提供以下能力：对所有七个项目开发的化合物进行严格的体外和体内测试，强调提供无与伦比的BSL 3和ABSL 3容量。我们将快速有效地完善我们的目标在我们的项目过程中，从一系列进行/不进行决策中进行向下选择，结构，以快速识别最有前途的候选人在体外和体内。化合物将在预防和治疗模型。由于我们的项目采取独特的方法来针对病毒的生命周期，还将对每个项目的主要候选人进行综合测试，以确定协同作用。最有前途的然后，将发送的主要候选人在翻译加速器核心的进一步发展。到为了完成这项工作，我们汇集了一支杰出的跨学科研究团队，在病毒学、药物开发和药物筛选的啮齿动物模型方面有丰富的经验。我们还带来了使用人体气液界面（ALI）在生理系统中测试化合物的高度创新方法模型和人类成人肺类器官（ALO）。我们的目标是提供行业水平的筛选能力，选择最有前途的候选药物。